3,3'-oxybis(pyridine) | 53258-95-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,3'-oxybis(pyridine)
• 英文别名: 3,3'-oxybispyridine；3,3'-oxydipyridine；3-pyridinyl oxide；3-Pyridyl ether；3-pyridin-3-yloxypyridine
• CAS: 53258-95-0
• 化学式: C₁₀H₈N₂O
• 分子量: 172.186
• InChiKey: VZUJTDYSGISPLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3,3'-oxybis(pyridine) 以 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Smart Molecular Helical Springs as Tunable Receptors

  摘要：

  The rational construction and operation of an ideal helical spring has been investigated. The infinite helices, [Ag(Py2O)]X (Py2O = 3,3'-oxybispyridine; X- = NO3-, BF4-, ClO4-, and PF6-), have been constructed in high yield via cooperative effects of the skewed conformer of Py2O and the potential linear geometry of the N-Ag(I)-N bond. Crystallographic characterization reveals that the polymer framework is an ideal cationic cylindrical helix and that its counteranions are pinched in two columns inside the helix. The four anions have been exchanged fur each other in an aqueous solution without destruction of the helical skeleton. In particular; [Ag(Py2O)]NO3 prepared by the counteranion exchange can be isolated as crystals suitable for X-ray crystallography in water. The helical pitch is reversibly stretched via the counteranion exchange from 7.430(2) to 9.621(2) Angstrom, and is exactly proportional to the volume of the anion guests. This pitch-tuning is attributed to subtle change in the nonrigid dihedral angles between two pyridyl groups around O and Ag atoms that act as hinges within the helical subunit. Thermal analyses indicate that the helical compounds are stable up to 231-332 degreesC in the solid state.

  DOI：

  10.1021/ja001618b
• 作为产物：
  描述：

  3-溴吡啶-N-氧化物 在 氢氧化钾 、 铁粉 、 溶剂黄146 作用下， 反应 1.25h， 生成 3,3'-oxybis(pyridine)
  参考文献：
  名称：

  Cognition-activating properties of 3-(aryloxy)pyridines

  摘要：

  A series of 3-(aryloxy)pyridines was found to possess activity in enhancing retention for passive avoidance learning in mice. This test was used to select compounds with potential therapeutic properties for the treatment of cognitive disorders. Reference drugs that gave positive results in this procedure included d-amphetamine, magnesium pemoline, methyl phenidate, picrotoxin, phenytoin, and ethosuximide. All active compounds gave inverted U-shaped dose-response curves. The most active compounds of the 3-(aryloxy)pyridines included 3-phenoxypyridine (1), 3-(2-fluorophenoxy)pyridine (2), 3-(4-fluorophenoxy)pyridine (4), 3,3'-oxybis(pyridine) (23), and 3,3'-oxybis(pyridine) 1-oxide (24). 3-Phenoxypyridine (1) was clearly superior to all of the analogues tested in terms of the level of retention, grammometric potency, and the breadth of its inverted U-shaped dose-response curve. It was given the designation of CI-844 and after a detailed study of its pharmacological profile was submitted for preclinical toxicology.

  DOI：

  10.1021/jm00135a020

文献信息

• [EN] INHIBITORS OF ADENYLATE-FORMING ENZYME MENE<br/>[FR] INHIBITEURS DE L'ENZYME MENE FORMANT L'ADÉNYLATE CYCLASE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2020163673A1

  公开（公告）日：2020-08-13

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts or tautomers thereof which may inhibit adenylate-forming enzymes. Also provided are pharmaceutical compositions, kits, uses, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., tuberculosis, methicillin- resistant Staphylococcus aureus)).

  本文提供了式（I）的化合物及其药用可接受的盐或互变异构体，这些化合物可能抑制腺苷酸形成酶。还提供了涉及这些创新化合物用于治疗和/或预防传染病（例如细菌感染（例如结核病、耐甲氧西林金黄色葡萄球菌））的药物组合物、试剂盒、用途和方法。
• Synthesis of β-heteroaryl carbonyl compounds via direct cross-coupling of allyl alcohols with heteroaryl boronic acids under cooperative bimetallic catalysis
  作者：Mingxiang Zhu、Hongli Du、Jingya Li、Dapeng Zou、Yusheng Wu、Yangjie Wu

  DOI：10.1016/j.tetlet.2018.02.021

  日期：2018.4

  The eco-friendly cooperative Cu/Pd-catalyzed oxidative Heck reaction of allyl alcohols with heteroaryl boronic acids under air was described. The ready availability of starting materials and the mild reaction conditions made this protocol a safe and operationally convenient strategy for the efficient synthesis of β-heteroaryl carbonyl compounds.

  描述了空气中烯丙醇与杂芳基硼酸的生态友好的铜/钯催化的协同氧化Heck反应。起始原料的易得性和温和的反应条件使该方案成为有效合成β-杂芳基羰基化合物的安全且操作便捷的策略。
• [EN] MORPHOLINO COMPOUNDS, USES AND METHODS<br/>[FR] COMPOSÉS MORPHOLINO, UTILISATIONS ET PROCÉDÉS
  申请人：UNIV DUNDEE

  公开号：WO2012160392A1

  公开（公告）日：2012-11-29

  The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.

  该发明涉及根据式（I）的吗啡啉衍生物或其立体异构体或药用可接受的盐或溶剂化物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、m和n如规范中定义。这些化合物是G蛋白偶联受体的拮抗剂、逆向激动剂或激动剂，例如多巴胺D4和5HT1a。该发明还涉及包括这些化合物的药物组合物和涉及这些化合物和组合物的方法。该发明的化合物和组合物特别可用于治疗疾病和疾病，如神经和神经退行性疾病；或作为设计和选择更多治疗化合物的引导化合物。
• MORPHOLINO COMPOUNDS, USES AND METHODS
  申请人：University of Dundee

  公开号：US20140148452A1

  公开（公告）日：2014-05-29

  The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.

  该发明涉及按照式(I)的吗啡啉衍生物或其立体异构体或药用可接受的盐或溶剂，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、m和n如规范中定义。这些化合物是G蛋白偶联受体的拮抗剂、反向激动剂或激动剂，例如多巴胺D4和5HT1a。该发明还涉及包括这些化合物的药物组合物和涉及这些化合物和组合物的方法。该发明的化合物和组合物特别可用于治疗疾病和障碍，如神经系统和神经退行性疾病；或作为设计和选择进一步治疗化合物的引导化合物。
• ISATIN ANALOGUES AND USES THEREFOR
  申请人：Mach Robert H.

  公开号：US20090068105A1

  公开（公告）日：2009-03-12

  Novel isatin analogues, including isatin analogues comprising Michael Acceptors (IMAs) are disclosed. Further disclosed are methods of synthesis of the isatin analogues, and uses of the analogues, including inhibition of caspase-3 and caspase-7, and in vivo imaging of apoptosis by Positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

  揭示了新颖的吲哚类似物，包括具有Michael受体的吲哚类似物（IMAs）。进一步揭示了吲哚类似物的合成方法，以及类似物的用途，包括抑制caspase-3和caspase-7，以及通过正电子发射断层扫描（PET）或单光子发射计算机断层扫描（SPECT）对凋亡进行体内成像。